Rubicon Research Ltd Q1 FY27 Results Analysis: PAT Nearly Doubles, Revenue Surges 51.6%

Rubicon Research Ltd's Q1 FY27 numbers came in strong, with revenue of Rs. 534.34 Cr (+51.60% YoY) and PAT growth of +95.80% YoY. Here's a quick read of what worked, what to watch, and what management said.

Quarter Snapshot

Q1 FY27 consolidated revenue grew 51.6% YoY to Rs.534.34 Cr and PAT nearly doubled to Rs.84.78 Cr, with EBITDA margin of 24.16% above the 22–23% guided band. Operating leverage, lower finance costs and rupee depreciation drove the margin beat, while the Arinna acquisition added two months of revenue. Watch items: Pithampur FDA observations and margin-dilutive subsidiaries.

Key Investment Insights

Key Positives

• Consolidated revenue grew 51.6% YoY to Rs.534.34 Cr and 4.0% QoQ.
• EBITDA margin was 24.16%, above the management's 22–23% guidance band and up from 22.44% YoY.
• PAT grew 95.8% YoY to Rs.84.78 Cr; diluted EPS rose to Rs.5.08 from Rs.2.79.
• Gross margin improved to 68.38% from 67.06% in Q4 FY26, within the 67–68% target.
• Finance costs fell 12.5% YoY to Rs.9.29 Cr; borrowings reduced from ~Rs.393 Cr to ~Rs.259 Cr.
• R&D expense was 11.24% of revenue, within the guided 10–11% range.

Risk Factors

• Pithampur facility received 2 procedural FDA 483 observations with no closure update in the filing.
• Subsidiaries are margin-dilutive: consolidated EBITDA margin 24.16% vs standalone 29.18%; subsidiary PBT was a Rs.0.29 Cr drag and PAT contribution was Rs.2.33 Cr.
• Employee benefits expense rose 47.2% YoY and 25.3% QoQ.
• IPO proceeds of Rs.805.69 Mn remained unutilised as of 30 June 2026; deployment timeline extended to 31 March 2027.